Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Operating Leases data on file, last reported at $61.4 million in Q1 2026.

• Quarterly Operating Leases fell 23.72% year-over-year to $61.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.4 million (down 23.72% YoY) and the FY2025 annual result came in at $66.8 million, down 64.81% from the prior year.
• Operating Leases fell to $61.4 million in Q1 2026 per NTLA's latest filing, from $66.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $190.0 million in Q4 2024 and bottomed at $60.0 million in Q2 2022.
• The 5-year median for Operating Leases is $84.1 million (2022), against an average of $90.6 million.
• The widest annual swing landed in 2024, when Operating Leases soared 96.34%; it then sank 64.81% in 2025.
• Tracing NTLA's Operating Leases over 5 years: stood at $114.0 million in 2022, then retreated by 15.15% to $96.7 million in 2023, then surged by 96.34% to $190.0 million in 2024, then slumped by 64.81% to $66.8 million in 2025, then dropped by 8.16% to $61.4 million in 2026.
• Per Business Quant, the three latest NTLA Operating Leases figures stand at $61.4 million (Q1 2026), $66.8 million (Q4 2025), and $70.6 million (Q3 2025).

Peer Comparison